Skip to main content
ADALTA LIMITED logo

ADALTA LIMITED — Investor Relations & Filings

Ticker · 1AD ISIN · AU0000001AD2 LEI · 254900XT3BQIT6GR6M94 ASX Professional, scientific and technical activities
Open in API
Filings indexed 726 across all filing types
Latest filing 2023-12-19 Director's Dealing
Country AU Australia
Listing ASX 1AD

About ADALTA LIMITED

https://adalta.com.au/

AdAlta Limited is a clinical-stage biotechnology company focused on the discovery and development of a new class of protein therapeutics called i-bodies. The company utilizes its proprietary i-body platform to engineer highly stable, small-format proteins that mimic the binding characteristics of shark antibodies. These i-bodies are designed to target complex disease-related proteins that are often inaccessible to traditional monoclonal antibodies. AdAlta's lead therapeutic candidate, AD-214, is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic conditions. The platform's versatility allows for the creation of diverse therapeutic leads across multiple disease areas, including inflammation and oncology, by leveraging the unique structural properties of the human protein scaffold-based i-body library.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice (TO) 4 pages 275.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including number of shares and options held before and after the change, nature of the change, and dates. This is a formal notification of personal share transactions by a company director. The document is not a financial report, earnings release, or management discussion, but a regulatory disclosure of insider trading activity by a director. Therefore, it fits the category of Director's Dealing (DIRS). The document length and content fully support this classification with high confidence.
2023-12-19 English
Change of Director's Interest Notice x 4 (TO, PM, DF & RP) 13 pages 524.7KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including number of securities held before and after changes, nature of interests, and dates of changes. The document is a formal notification of personal share transactions by company directors. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report but a direct report of insider transactions. Therefore, it fits the category of Director's Dealing (DIRS). The document length is substantial and contains detailed transaction data, supporting a high confidence classification.
2023-12-18 English
Application for quotation of securities - 1AD 6 pages 27.7KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX by Adalta Limited. It details the number and type of securities to be quoted, references previous announcements (Appendix 3B), and provides information about the issued capital following the quotation. There are no financial statements, earnings data, or management discussion. The document is an announcement related to capital market activity, specifically the quotation of securities, which aligns with capital or financing updates. Therefore, the document fits best under the Capital/Financing Update (CAP) category.
2023-12-18 English
Application for quotation of securities - 1AD 7 pages 30.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Application for quotation of +securities' and details the application to list new securities on the ASX. It includes information about the entity, the securities to be quoted, issue dates, distribution schedules, and issued capital following quotation. The document references previous announcements (Appendix 3B) related to the securities issuance. There are no financial statements, management discussion, or earnings data present. The content is focused on the administrative process of securities quotation rather than financial reporting or corporate governance changes. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2023-12-18 English
Application for quotation of securities - 1AD 6 pages 27.7KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the securities to be quoted, their issue dates, and related issuance information. It references previous announcements and Appendix 3B filings, which are typical for new securities issuance and quotation requests. The document does not contain financial statements, management discussion, or earnings data. It is an announcement related to capital market activity, specifically the quotation of securities already issued or to be issued. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-12-18 English
New malaria inhibiting i-body 3 pages 202.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 19 December 2023 from AdAlta Limited. It details a scientific breakthrough in malaria treatment involving their proprietary i-body technology platform. The content focuses on research collaboration results, patent filing, publication of a pre-print manuscript, and future development plans. There are no financial statements, earnings data, or regulatory certifications included. The document is a corporate announcement about a scientific and intellectual property development rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the discovery and its implications, not just a notice of report availability. Therefore, the document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as earnings release, capital update, or management report.
2023-12-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.